UCB The Bimekizumab grand slam: HS after PsO, PsA and AxspA
After compelling clinical results for Bimzelx in psoriasis, psoriatic arthritis and axial spondylarthritis, UCB has now revealed the topline results in hidradenitis suppurativa (HS). The fourth indication in which the drug shines is an interesting one, as HS is still somewhat an untapped vessel in the immunology space. Today, Humira and infliximab are the only biologics used in the treatment of moderate to severe HS, and infliximab is being used off label. Although it is not the best practice to compare drugs across clinical trials, Bimzelx seems to be on par with Humira at week 12; but at week 48, the results appear superior. We re-iterate our Buy rating and we maintain our €110 target price.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.